Trials / Unknown
UnknownNCT03369990
DWP450 Treatment in Subjects With Benign Masseteric Hypertrophy
A Randomized, Double-blind, Placebo-controlled, Phase Ⅱ Optimal Dose-finding Study to Determine the Safety and Efficacy of DWP450 in Subjects With Benign Masseteric Hypertrophy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 98 (estimated)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is A Randomized, Double-blind, Placebo-controlled, Phase II Optimal Dose-finding Study to Determine the Safety and Efficacy of DWP450 in Subjects with Benign Masseteric Hypertrophy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Botulinum toxin type A | Botulinum toxin type A(DWP450) |
| DRUG | Placebos | Normal Saline |
Timeline
- Start date
- 2017-12-01
- Primary completion
- 2018-10-01
- Completion
- 2018-10-01
- First posted
- 2017-12-12
- Last updated
- 2017-12-12
Source: ClinicalTrials.gov record NCT03369990. Inclusion in this directory is not an endorsement.